Japanese contributions to oncology drug development and regulatory approval around the world

被引：0
|
作者：
Fujiwara, Yasuhiro [1 ]
Nonaka, Takahiro [1 ]
机构：
[1] Pharmaceut & Med Devices Agcy, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-6
引用
收藏
页码：954 / 954
页数：1
相关论文
共 50 条
  • [1] Oncology 2020: a drug development and approval paradigm
    Dhingra, K.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2347 - 2350
  • [2] Accelerated Approval and Oncology Drug Development Timelines
    Lanthier, Michael L.
    Sridhara, Rajeshwari
    Johnson, John R.
    Farrell, Ann
    Keegan, Patricia
    Justice, Robert
    Pazdur, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : E226 - E227
  • [3] Real-world evidence and regulatory drug approval
    Michael J. Raphael
    Bishal Gyawali
    Christopher M. Booth
    Nature Reviews Clinical Oncology, 2020, 17 : 271 - 272
  • [4] Real-world evidence and regulatory drug approval
    Raphael, Michael J.
    Gyawali, Bishal
    Booth, Christopher M.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (05) : 271 - 272
  • [5] An overview of the regulatory approval process in drug development
    Chow, SC
    Pong, A
    DRUG INFORMATION JOURNAL, 1998, 32 : 1175S - 1185S
  • [6] Accelerated Approval and Oncology Drug Development Timelines Reply
    Bennett, Charles L.
    Nebeker, Jonathan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (14) : E228 - E228
  • [7] Drug Development in Oncology: A Regulatory Perspective
    Augustus, Stella
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (04) : 323 - 331
  • [8] Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
    Al-Huniti, Nidal
    Feng, Yan
    Yu, Jingyu Jerry
    Lu, Zheng
    Nagase, Mario
    Zhou, Diansong
    Sheng, Jennifer
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (08): : 419 - 427
  • [9] Drug development in oncology and devices—lessons for heart failure drug development and approval? a review
    Beth A. Davison
    Gad Cotter
    Gerasimos S. Filippatos
    Faiez Zannad
    Adriaan A. Voors
    Marco Metra
    John R. Teerlink
    Stefanie Senger
    Alexandre Mebazaa
    Barry Greenberg
    Heart Failure Reviews, 2021, 26 : 255 - 262
  • [10] FDA regulatory considerations for oncology drug development
    Moon, Hanlim
    Zang, Dae Young
    Ryu, Min-Hee
    Seo, Yeonsook
    Oh, Bitna
    Hwang, Sunjin
    Farrand, Lee
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
12345